Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition

Ruud S Kootte, Evgeni Levin, Jarkko Salojärvi, Loek P Smits, Annick V Hartstra, Shanti D Udayappan, Gerben Hermes, Kristien E Bouter, Annefleur M Koopen, Jens J Holst, Filip K Knop, Ellen E Blaak, Jing Zhao, Hauke Smidt, Amy C Harms, Thomas Hankemeijer, Jacques J G H M Bergman, Hans A Romijn, Frank G Schaap, Steven W M Olde DaminkMariette T Ackermans, Geesje M Dallinga-Thie, Erwin Zoetendal, Willem M de Vos, Mireille J Serlie, Erik S G Stroes, Albert K Groen, Max Nieuwdorp

    Research output: Contribution to journalArticleAcademicpeer-review

    250 Citations (Scopus)


    The intestinal microbiota has been implicated in insulin resistance, although evidence regarding causality in humans is scarce. We therefore studied the effect of lean donor (allogenic) versus own (autologous) fecal microbiota transplantation (FMT) to male recipients with the metabolic syndrome. Whereas we did not observe metabolic changes at 18 weeks after FMT, insulin sensitivity at 6 weeks after allogenic FMT was significantly improved, accompanied by altered microbiota composition. We also observed changes in plasma metabolites such as γ-aminobutyric acid and show that metabolic response upon allogenic FMT (defined as improved insulin sensitivity 6 weeks after FMT) is dependent on decreased fecal microbial diversity at baseline. In conclusion, the beneficial effects of lean donor FMT on glucose metabolism are associated with changes in intestinal microbiota and plasma metabolites and can be predicted based on baseline fecal microbiota composition.

    Original languageEnglish
    Pages (from-to)611-619.e6
    JournalCell metabolism
    Issue number4
    Publication statusPublished - 2017


    • Journal Article

    Cite this